Status:
UNKNOWN
Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma
Lead Sponsor:
sohaila Essam
Conditions:
Brain Tumor Adult
Eligibility:
All Genders
18-85 years
Brief Summary
The study population was selected from high grade glioma pateints attending the Department of Clinical Oncology, Assiut University hospital during the period from December 2018 to September 2020, we a...
Detailed Description
Glioblastoma is the most common malignant primary brain tumor in adults, and despite aggressive treatment, it is incurable Patient prognosis differs considerably within the different World Health Orga...
Eligibility Criteria
Inclusion
- Pateints\>18 years old
- Pathologically proven high grade glioma
- Total or subtotal resection of the tumor
- Patients received concurrent radiation therapy with temozolomide followed by adjuvant temozolamide for 6 months
Exclusion
- Pregnancy
- Breast feeding
- Other comorbidity
- Previous malignancy or radiation therapy or chemotherapy
Key Trial Info
Start Date :
November 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2021
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT04113278
Start Date
November 1 2019
End Date
September 1 2021
Last Update
October 2 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.